Live price temporarily unavailable.
Lineage Cell Therapeutics (LCTX) is a Health Care company in the Russell 2000. Latest news and coverage below.
Lineage Cell Therapeutics revenue & net income history (FY2016–FY2025)
| FY2016Dec 2016 | FY2017Dec 2017 | FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $5.92M | $3.46M | $4.99M | $3.52M | $1.83M | $4.34M | $14.7M | $8.95M | $9.50M | $14.6M |
| Growth (year over year) | −15.8% | −41.6% | +44.2% | −29.5% | −48.1% | +137.7% | +238.7% | −39.2% | +6.2% | +53.2% |
| Gross profit | $5.57M | $3.29M | $4.69M | $3.10M | $1.44M | $2.92M | $14.0M | $8.27M | $9.16M | — |
| Gross margin | 94.0% | 95.1% | 93.9% | 88.3% | 78.9% | 67.2% | 95.0% | 92.5% | 96.5% | — |
| Operating income | −$59.0M | −$38.9M | −$41.8M | −$38.9M | −$26.4M | −$49.2M | −$22.5M | −$24.7M | −$21.5M | −$36.6M |
| Operating margin | −995.6% | −1125.0% | −837.9% | −1106.0% | −1448.4% | −1133.6% | −153.2% | −276.5% | −226.1% | −251.6% |
| Net income | $33.6M | −$20.0M | −$46.0M | −$11.7M | −$20.6M | −$43.0M | −$26.3M | −$21.5M | −$18.6M | −$63.5M |
| Net margin | 566.8% | −577.7% | −922.0% | −333.1% | −1130.8% | −991.0% | −178.7% | −240.2% | −195.9% | −436.5% |
| EPS (diluted) | $0.34 | −$0.17 | −$0.36 | −$0.08 | −$0.14 | −$0.26 | −$0.15 | −$0.12 | −$0.09 | −$0.28 |
| Balance sheet | ||||||||||
| Cash and equivalents | $22.1M | $36.8M | $23.6M | $9.50M | $32.6M | $55.7M | $11.4M | $35.4M | $45.8M | $40.8M |
| Total assets | $142.6M | $173.2M | $101.7M | $125.5M | $107.9M | $174.5M | $123.7M | $101.0M | $113.2M | $112.6M |
| Total liabilities | $12.1M | $8.98M | $9.41M | $14.2M | $12.8M | $83.6M | $51.7M | $39.0M | $36.2M | $69.2M |
| Shareholders' equity | $117.9M | $162.6M | $92.2M | $113.0M | $96.2M | $92.2M | $73.3M | $63.4M | $78.4M | $44.5M |
| Cash flow | ||||||||||
| Operating cash flow | −$42.3M | −$30.5M | −$30.9M | −$31.9M | −$19.8M | −$23.6M | $1.06M | −$28.6M | −$23.1M | −$18.9M |
| Capital expenditure | $2.25M | $1.33M | $556.0K | $440.0K | $64.0K | $340.0K | $413.0K | $674.0K | $565.0K | $522.0K |
| Free cash flow | −$44.6M | −$31.8M | −$31.4M | −$32.4M | −$19.8M | −$23.9M | $646.0K | −$29.2M | −$23.7M | −$19.4M |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $3.78M | $2.87M | $1.50M | $2.77M | $3.68M | $6.61M | $1.73M | $1.07M |
| Growth (year over year) | +203.3% | +37.4% | +4.0% | +96.4% | −2.6% | +130.4% | +14.8% | −61.3% |
| Gross profit | $3.74M | $2.71M | $1.47M | — | — | — | — | — |
| Gross margin | 99.0% | 94.6% | 97.6% | — | — | — | — | — |
| Operating income | −$3.84M | −$5.11M | −$6.50M | −$19.8M | −$3.79M | −$6.55M | −$7.59M | −$8.92M |
| Operating margin | −101.6% | −178.2% | −433.1% | −715.4% | −102.9% | −99.1% | −440.2% | −834.7% |
| Net income | −$3.03M | −$3.27M | −$4.14M | −$30.5M | −$29.8M | $851.0K | −$4.81M | $1.48M |
| Net margin | −80.3% | −114.1% | −275.6% | −1101.8% | −809.0% | 12.9% | −279.0% | 138.6% |
| EPS (diluted) | −$0.02 | $0.00 | −$0.02 | −$0.13 | −$0.13 | $0.00 | −$0.03 | −$0.03 |
| Balance sheet | ||||||||
| Cash and equivalents | $27.8M | $45.8M | $47.9M | $42.3M | $40.5M | $40.8M | $35.9M | $37.4M |
| Total assets | $96.6M | $113.2M | $111.8M | $90.8M | $89.6M | $112.6M | $109.5M | $106.2M |
| Total liabilities | $31.8M | $36.2M | $34.1M | $43.7M | $68.8M | $69.2M | $56.8M | $46.4M |
| Shareholders' equity | $66.2M | $78.4M | $79.0M | $48.4M | $22.0M | $44.5M | $53.9M | $60.9M |
| Cash flow | ||||||||
| Operating cash flow | −$5.79M | −$6.35M | −$4.89M | −$5.54M | −$3.62M | −$4.88M | −$8.08M | −$7.24M |
| Capital expenditure | $112.0K | $365.0K | $97.0K | $14.0K | $12.0K | $399.0K | $55.0K | $108.0K |
| Free cash flow | −$5.90M | −$6.71M | −$4.98M | −$5.55M | −$3.63M | −$5.28M | −$8.13M | −$7.35M |
From Lineage Cell Therapeutics's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About Lineage Cell Therapeutics
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform, Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer.
Source: Wikipedia — Lineage Cell Therapeutics
- Headquarters
- Carlsbad, California From SEC filings, Oct 2026
Recent News
No recent news mentioning Lineage Cell Therapeutics in our feed yet.
More Health Care stocks
- ILMN Illumina
- A Agilent Technologies
- ABBV AbbVie
- ABT Abbott Laboratories
- ALGN Align Technology
- ALNY Alnylam Pharmaceuticals
- AMGN Amgen
- BAX Baxter International